Dr. Thomas S. Edwards, MD
ENT (Otolaryngology) (Otolaryngic Allergy Physician)
- Medicare participating
At a glance
- Medical school
- Tulane University School of Medicine (2016)
- Years since graduation
- 10
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 152
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Medical school: Tulane University School of Medicine
- 2016Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Otolaryngic Allergy Physician primary
GA license 91581 -
Otolaryngology Physician
GA license 91581
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Emory University Hospital Midtown Atlanta, GA
- Saint Joseph's Hospital of Atlanta, Inc Atlanta, GA
- Emory Decatur Hospital Decatur, GA
Medical groups
- The Emory Clinic Inc (3,568 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 152
- Services billed
- 421
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Diagnostic exam of nasal passages using an endoscope | 150 | 116 |
| New patient office or other outpatient visit, 45-59 minutes | 64 | 64 |
| Established patient office or other outpatient visit, 20-29 minutes | 49 | 38 |
| Established patient office or other outpatient visit, 30-39 minutes | 48 | 40 |
| New patient office or other outpatient visit, 30-44 minutes | 35 | 35 |
| Removal of impacted ear wax | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Azelastine Hcl Other prescribers in Decatur, GA | 145 |
| Fluticasone Propionate Other prescribers in Decatur, GA | 108 |
| Ipratropium Bromide Other prescribers in Decatur, GA | 96 |
| Mometasone Furoate Other prescribers in Decatur, GA | 44 |
| Doxycycline Hyclate Other prescribers in Decatur, GA | 28 |
| Mupirocin Other prescribers in Decatur, GA | 24 |
| Prednisone Other prescribers in Decatur, GA | 19 |
| Dupixent Pen (dupilumab) Other prescribers in Decatur, GA | 15 |
| Oxycodone Hcl Other prescribers in Decatur, GA | 15 |
| Amoxicillin-Clavulanate Potass (amoxicillin/potassium clav) Other prescribers in Decatur, GA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $28.24 in total to this clinician.
| Stryker Corporation | $28.24 |
|---|
| Food and Beverage | $28.24 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $775,500 in research payments for these studies, mostly to the institutions running them.
- A randomized, 52-week treatment double-blind, placebo-controlled efficacy and safety study of dupilumab 300 mg every other week after endoscopic sinus surgery in patients with AFRS on a background therapy with intrana…
Genzyme Corporation - A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps
Sanofi US Services Inc. · Completed · NCT06454240 - A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Sanofi US Services Inc. · Active, not recruiting · NCT06834347
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.